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In this issue of Neuron, Stachniak et al. (2014) determine that the chemogenetic silencer hM4Di-DREADD
suppresses presynaptic glutamate release, and by generating an axon-targeted hM4Di variant they demon-
strate that it can be used to locally silence synaptic transmission in neural circuits.‘‘Silence is all we dread.
There’s Ransom in a Voice —
But Silence is Infinity.’’ (Emily
Dickinson, Poem 1251, Complete
Poetry of Emily Dickenson)
Some decades ago, Francis Crick pre-
sciently predicted that in order for
scientists to elucidate the ‘‘neuronal
codes’’ that specify behavior, perception,
and consciousness, ‘‘a method (is
needed) by which all neurons of just
one type could be inactivated, leaving
the others more or less unaltered’’ (Crick,
1979). Now, of course, both optogenetic
(Zhang et al., 2007) and chemogenetic
(Armbruster et al., 2007) technologies
are widely available for silencing neurons
‘‘of just one type.’’ Simply inhibiting cell
body firing and observing the resulting
behavioral phenotype, unfortunately,
does little to elucidate which specific
projections or target areas might be
responsible for the observed effects (see
Figure 1A). Ideally, what is needed is a
technology that can specifically and
reversibly silence presynaptic nerve ter-
minals, thereby ‘‘silencing synapses’’
projecting to distinct neuronal popula-
tions (Figure 1B). A technological leap
forward is now reported by Stachniak
et al. (2014), who via clever modifications
of the DREADD chemogenetic platform
achieved synaptic silencing.
As first described, the hM4Di-DREADD,
when stimulated by clozapine-N-oxide
(CNO), activates G protein inwardly recti-
fying potassium (GIRK) channels, thereby
hyperpolarizing and attenuating neuronal
activity (Armbruster et al., 2007). hM4Di
is now routinely used as a tool to diminish
the activity of genetically defined neurons
in vitro and in vivo (Atasoy et al., 2012;
Ferguson et al., 2011; Krashes et al.,
2011; Ray et al., 2011; Carter et al.,2013). The robust effects of hM4Di acti-
vation on physiology (see Ray et al.,
2011 for example) and behavior (see
Carter et al., 2013 for instance) have
been difficult to reconcile with the rela-
tively modest ability of hM4Di to hyper-
polarize and attenuate neuronal firing
in vitro (see, for instance, Ferguson
et al., 2011; Krashes et al., 2011; Ray
et al., 2011). Here, Stachniak et al.
(2014) confirm that hM4Di activation leads
to hyperpolarization and attenuation of
neuronal firing but also discovered a
much more potent action of hM4Di as an
effective synaptic silencer in slice pre-
parations and in vivo. It is this silencing
of synaptic transmission that will ulti-
mately expand the utility of DREADD-
based technology for deconstructing the
neuronal code.
Using postsynaptic current as the
readout, they first tested whether the
CNO-induced activation of hM4Di in a
presynaptic neuron suppresses synaptic
transmission to postsynaptic neurons
located in the same or in different layers
of the cortex. They discovered that
CNO-induced activation of hM4Di L2/3
presynaptic cortical neurons robustly in-
hibited the postsynaptic current in both
L2/3 neurons and L5 neurons. They also
demonstrated that this inhibition of the
postsynaptic current was not due to
blockade of either the initiation or the
propagation of the axonal action poten-
tial. Instead, hM4Di appeared to act by
suppressing L2/3 synaptic glutamate
release. Importantly, neither CNO admin-
istered in control slices nor basal hM4Di
activity had any significant effect on
synaptic glutamate release from L2/3
glutamatergic neurons.
To determine whether this ‘‘synaptic
silencing’’ by hM4Di could be useful for
studies in vivo, Stachniak et al. (2014)Neuronchose a well-characterized and popular
neural circuit for food intake and
examined synaptic transmission from
Agouti-related peptide (AgRP)-express-
ing neurons in the arcuate nucleus of the
hypothalamus (ARC) to paraventricular
hypothalamic (PVH) neurons (Stachniak
et al., 2014). Prior studies showed that
PVH neurons receive axonal projections
from AgRP neurons and mediate food
intake evoked by activation of AgRP
neurons (Atasoy et al., 2012). Stachniak
et al. (2014) then coexpressed channelr-
hodopsin2 (ChR2) and hM4Di in AgRP
neurons and examined the effect of CNO
on light-evoked food intake. Astound-
ingly, they found that microinfusion of
CNO above the PVH, but not in an area
only 300–500 mmdistant, reduced feeding
by 50% during AgRP neuron photosti-
mulation. Taken together, the results
obtained from studies in the cortex and
hypothalamus demonstrate that hM4Di
can effectively suppress presynaptic
transmission both ex vivo and in vivo. In
support of this notion, a recent report
(Mahler et al., 2014) showed that micro-
infusion of CNO suppresses terminal
dopamine release in hM4Di-expressing
dopaminergic axons.
As hM4Di is normally localized to
both neuronal cell bodies and axons
(Mahler et al., 2014; Zhu et al., 2014),
it would be more useful to target it spe-
cifically to the axonal compartment
to achieve selective suppression of
synaptic transmission. To achieve this,
Stachniak et al. (2014) developed an
axon-preferring variant of hM4Di they
refer to as hM4DNRXN, as it contained
the axonal C-terminal targeting sequence
of Neurexin1a. This hM4DiNRXN variant
displayed reduced somatic expression
and enhanced selective axonal expres-
sion. Activation of the hM4DNRXN variant82, May 21, 2014 ª2014 Elsevier Inc. 723
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Figure 1. Spatially Precise Synaptic Silencing
As shown in (A), hM4Di is expressed mainly in the cell bodies and axon. Systemic CNO administration
leads to hyperpolarization and suppression of electrical activity (depicted in the diagram by the black-
colored neuron) in a prototypic glutamatergic neuron. As described by Stachniak et al. (2014), a global
suppression of presynaptic glutamate release also occurs (black synaptic terminals) via synaptic
silencing. The net effect is less excitatory drive of anatomically distinct neurons (which are colored blue
to indicate lower excitatory drive). In (B), a glutamatergic neuron expresses hM4DNRXN mainly in axonal
projections. Here a microinfusion of CNO does not induce somatic hyperpolarization and as a result the
overall activity of the neuron is unchanged (colored yellow indicating robust spontaneous activity). Micro-
infusion of CNO suppresses presynaptic release of glutamate, leading to less excitatory drive of only neu-
rons in the region perfused (blue) without altering activity of other neurons (red).
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transmission but did not induce somatic
hyperpolarization and thereby selectively
silenced synaptic transmission.
Using this synaptic silencing tool,
Stachniak et al. (2014) then de-
constructed the neural circuit down-
stream of the PVH to demonstrate
the further utility of this improved
DREADD. Thus, the hM4DNRXN variant
was expressed in PVHSIM1 (single-minded
homolog 1 [SIM1]) neurons, and CNO
was microinfused into the multiple
brain regions targeted by PVHSIM1 axon
projections. Stachniak et al. (2014)
reported that inhibition of the PVHSIM1/
NTS/DVC (nucleus of the solitary
tract and dorsal vagal complex [NTS/
DVC]) axon projection was not sufficient
to evoke food intake behavior. How-
ever, they identified another ‘‘hotspot,’’
the caudal ventrolateral periaque-
ductal gray and dorsal raphe complex,
as a key node downstreamof ARCAGRP/
PVH neural circuit that controls food
intake.724 Neuron 82, May 21, 2014 ª2014 ElsevierThe study by Stachniak et al. (2014)
addresses two important issues related
to DREADD technology. First, they pro-
vide convincing evidence that activation
of hM4Di in presynaptic terminals can
suppress synaptic transmission without
disturbing somatic or axonal membrane
potentials. Therefore, hM4Di probably
silences neuronal activity in vivo via both
hyperpolarization and suppression of
presynaptic neurotransmitter release in a
manner analogous to that achieved by
presynaptic G-protein-coupled recep-
tors. This makes hM4Di unique among
the currently available optogenetic and
chemogenetic tools that silence neuronal
activity via hyperpolarizing neurons to
suppress action potentials. Second, they
demonstrate that microinfusion of CNO
into discrete brain regions is a reliable
way to achieve very precise spatiotem-
poral control of neuronal activity—in
agreement with a recent study (Mahler
et al., 2014).
This study also raises an intriguing
question regarding the mechanism byInc.which hM4Di inhibits presynaptic neuro-
transmitter release. Although GPCRs are
known to be ubiquitously expressed on
presynaptic terminals and to modulate
synaptic neurotransmitter release, how
hM4Di regulates neurotransmitter release
is unknown. It is not likely via GIRKS as
GIRK1 is primary localized in post-
synaptic rather than presynaptic termi-
nals (Drake et al., 1997) and GPCR
agonist-induced presynaptic inhibition
is unchanged in GIRK2 knockout
mice (Lu¨scher et al., 1997). Conceiv-
ably, hM4Di could induce presynaptic
silencing via inhibition of cAMP-mediated
signaling, which has been shown to
modulate the activity of voltage-gated
calcium channels in a model system (Hil-
fiker et al., 2001). Alternatively, hM4Di
could inhibit the SNARE exocytotic fusion
machinery downstream of calcium entry
through the action G protein bg subunits
(Gerachshenko et al., 2005).
Whatever themechanism, it is clear that
hM4Di can effectively suppress pre-
synaptic transmission both ex vivo and
in vivo, and this makes it useful for many
applications. Further, the axon-selective
hM4DNRXN variant developed in this study
is an exceedingly useful tool to function-
ally dissect neuronal circuitry by the
targeted inhibition of presynaptic trans-
mission without compromising the activ-
ities of other synapses originating from
the same neurons.REFERENCES
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How do neurons and networks achieve their characteristic electrical activity, regulate this activity homeo-
statically, and yet show population variability in expression? In this issue of Neuron, O’Leary et al. (2014)
address some of these thorny questions in this theoretical analysis that starts with the Central Dogma.Two seemingly opposed conceptual
threads wind through current experi-
mental and theoretical analyses of
neuronal and network activity. On the
one hand, neuronal and network activity
regimes are remarkably robust and can
homeostatically rebound from long-term
perturbation. This was first described in
pioneering theoretical studies and experi-
mental work employing neurons isolated
from the stomatogastric nervous system
of crustaceans. Such homeostatic
plasticity has now been observed and
modeled in cell culture, brain slices, and
in vivo across invertebrates and verte-
brates and has led to important concepts
such as synaptic scaling (Davis, 2006;
LeMasson et al., 1993; Marder and Goail-
lard, 2006; Turrigiano, 2007; Wenner,
2014). An evolving notion is that intracel-
lular [Ca2+]—fed by Ca2+ entry through
voltage-gated Ca2+ channels or Ca2+-
permeable synaptic channels—serves as
an effective signal of neuronal and
network activity (Liu et al., 1998; Turri-
giano, 2007). A corollary of this concep-
tual framework is that neurons with
different activity types differ in the suite
of membrane channels that they express
and the relative abundance of each
channel type. In invertebrates, where indi-
vidual cells are identifiable and have char-acteristic activity, this corollary has been
emphatically supported and similar evi-
dence exists for vertebrate neurons
(Marder, 2011).
On the other hand, many theoretical
studies—again starting in stomatogastric
nervous system—have indicated that
model neurons and networks can achieve
similar activity types with very different
complements of membrane and synaptic
channels (conductances) (Prinz et al.,
2004; Marder and Goaillard, 2006;
Marder, 2011). These theoretical studies
were followed by quantitative voltage-
clamp studies of expressed membrane
and synaptic channels, their maximal
conductances, and measurements of
channel mRNA levels in single neurons
(Amendola et al., 2012; Schulz et al.,
2007; Tobin et al., 2009). These
studies confirm the theoretical work
by showing that even with 3- to 5-fold
variation of channel conductances and
mRNA levels across individual animals,
similar neuronal and network activity is
observed.
How can these threads be woven
together? The beginnings of an answer
arise from the observation that in some
cases across individual animals, neuronal
maximal conductances (measured in
voltage clamp) and mRNA levels ofdifferent channel types (measured in
single cells) are, for some channels at
least, linearly correlated (Schulz et al.,
2007; Tobin et al., 2009). Theoretical
studies indicate that such linear cor-
relations of different membrane con-
ductances can maintain activity types
(Hudson and Prinz, 2010). It is a short
step then to speculate that homeostatic
regulatory mechanisms establish these
correlations. But how might such correla-
tions arise homeostatically? Past models
of homeostatic regulation of activity type
have not explicitly observed or sought
such correlations, until recently when
O’Leary and colleagues (O’Leary et al.,
2013) made a simple neuronal model
that showed how abstract ‘‘regulation’’
time constants determine correlations in
conductance expression at steady state.
In the current issue of Neuron, O’Leary
et al. (2014) extend and transform that
initial model by going back to basics.
Any modern college-level introductory
biology course begins with a unifying
principle of the biomolecular world: the
Central Dogma: DNA > (transcription)
mRNA > (translation) protein. One can
spend a whole semester on how tran-
scription (or for that matter translation) is
regulated. In O’Leary et al. (2014)’s new
model, they start with a universal82, May 21, 2014 ª2014 Elsevier Inc. 725
